1 week Ago By ABMN Staff
Prudential Financial Inc. purchased a new position in MaxCyte, Inc. ( NASDAQ:MXCT – Free Report ) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC).
The firm purchased 15,630 shares of the company’s stock, valued at approximately $65,000. Other hedge funds have also recently made changes to their positions in the company. Franklin Resources Inc.
acquired a new position in shares of MaxCyte in the third quarter valued at about $260,000. Barclays PLC lifted its stake in MaxCyte by 329.3% during the 3rd quarter.
Barclays PLC now owns 165,765 shares of the company’s stock valued at $645,000 after acquiring an additional 127,156 shares during the period. Geode Capital Management LLC increased its stake in shares of MaxCyte by 2.0% in the third quarter.
Geode Capital Management LLC now owns 2,474,632 shares of the company’s stock worth $9,628,000 after acquiring an additional 47,960 shares during the period. State Street Corp raised its holdings in shares of MaxCyte by 5.1% during the third quarter.
State Street Corp now owns 2,269,135 shares of the company’s stock worth $8,827,000 after purchasing an additional 111,066 shares during the last quarter. Finally, Rice Hall James & Associates LLC acquired a new position in MaxCyte during the fourth quarter valued at $1,098,000. 68.
81% of the stock is owned by institutional investors and hedge funds. MaxCyte Stock Performance Shares of NASDAQ MXCT opened at $2.58 on Friday.
The firm has a market cap of $274.29 million, a PE ratio of -7.59 and a beta of 1.
39. MaxCyte, Inc. has a one year low of $2.
21 and a one year high of $5.26. The firm has a fifty day moving average of $3.
34 and a 200 day moving average of $3.77. Analysts Set New Price Targets View Our Latest Report on MaxCyte MaxCyte Profile ( Free Report ) MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally.
Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. Further Reading Want to see what other hedge funds are holding MXCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MaxCyte, Inc.
( NASDAQ:MXCT – Free Report ). Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter .
.
